health News

Pfizer and BioNTech’s COVID19 Vaccine Trials in the US

Written by Tasha Ann Miller

November 20, 2020

Pfizer and BioNTech are seeking approval from the United States Food and Drug Administration (FDA) to authorize emergency use of their Covid19 vaccine.

Excerpt from Pfizer’s press release today on seeking U.S FDA approval

This emergency approval is critical as there is a continued rise in Covid19 cases in American. The multinational companu, Pfizer in partnership with BioNTech recently announced that their vaccines has a 95% success rate against the Covid19 virus.

Excerpt from Pfizer’s news release on November 18, 2020

The company is now undergoing the movement of vaccines to four US states (Tennesse, Rhode Island, Texas, and New Mexico) for trial. Pfizer’s partnership with BioNTech is one of the leading vaccination success in the fight to end the pandemic. Other companies like Moderna also reported a 94.5% effective vaccine. In China, the vaccine development and distribution has been largely unregulated by offical authorities like the World Health Organization (WHO), and people are reportedly receiving vaccines that are still going through testing.

Therefore, this clearly indicates that there will be several vaccines on the market once they are officially approved for distribution.

Pfizer and BioNTech’s vaccine is still unapproved for use outside of clinical trials. The Hope Vision will continue to monitor the latest updates on the progress of the varying stages, and urges you all to continue to stay safe.

By Tasha Miller

I am a Christian journalist with a passion for providing insightful and relevant information to the public. I write about education, politics, Christianity, and other areas. My focus is to provide factual and clear details so that people can be thoroughly equipped within this new age of media. I am a trained journalist with about three years of experience working in media professionally as a producer and production assistant. Follow my blog for dynamic and fresh content which will soon include exclusive content such as mini-documentaries, and feature pieces.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s